Macropinocytosis mediates resistance to loss of glutamine transport in triple-negative breast cancer

Kanu Wahi,Natasha Freidman,Qian Wang,Michelle Devadason,Lake-Ee Quek,Angel Pang,Larissa Lloyd,Mark Larance,Fabio Zanini,Kate Harvey,Sandra O’Toole,Yi Fang Guan,Jeff Holst

DOI: https://doi.org/10.1101/2024.02.21.581493

2024-02-22

Abstract:Triple-negative breast cancer (TNBC) relies on glutamine uptake by the transporter ASCT2 to sustain their unique glutamine metabolism and growth. Despite previous data showing cell growth inhibition after ASCT2 knockdown, ASCT2 CRISPR knockout was well-tolerated by breast cancer cell lines. Despite the loss of a glutamine transporter and low rate of glutamine uptake, intracellular glutamine steady state levels were higher in ASCT2 knockout compared to control TNBC cells. Proteomics data revealed upregulation of macropinocytosis, reduction in glutamine efflux and glutamine synthesis in ASCT2 knockout cells. Loss of ASCT2 in TNBC cell line HCC1806 induced a 5-10-fold increase in macropinocytosis across 5 separate ASCT2 knockout clones, compared to a modest 2-fold increase in the shRNA ASCT2 knockdown. By comparison, ASCT2 knockout impaired cell proliferation in a non-macropinocytic breast cancer cell line, HCC1569. These data suggest that macropinocytosis provides a novel resistance mechanism to strategies targeting glutamine uptake alone. Despite this adaptation, TNBC cells continue to rely on glutamine metabolism for their growth, which suggests therapeutic targeting may need to focus on downstream glutamine metabolism pathways.

Cancer Biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore how cells adapt to the change and continue to maintain their growth after the complete knockout of the glutamine transporter ASCT2 in triple - negative breast cancer (TNBC) cells. Specifically, the researchers are concerned with:

1. **The function of ASCT2 and its role in TNBC**: ASCT2 is an important glutamine transporter and is crucial for the growth of TNBC cells. However, although previous studies have shown that partial knockdown of ASCT2 can inhibit cell growth, complete knockout of ASCT2 does not lead to a significant impact on cell growth. This suggests that there may be other mechanisms to help cells adapt to the absence of ASCT2.

2. **Metabolic adaptation mechanisms**: Through a variety of experimental methods (such as proteomic analysis, metabolite tracking, etc.), the researchers found that after the complete knockout of ASCT2, TNBC cells compensate for the insufficient uptake of glutamine by up - regulating macropinocytosis. Macropinocytosis is a process by which cells engulf nutrients from the external environment, which may become a new mechanism for TNBC cells to resist ASCT2 - targeted therapy.

3. **Implications for treatment strategies**: Although TNBC cells adapt to the absence of ASCT2 through macropinocytosis, they still rely on glutamine metabolism to maintain growth. Therefore, the researchers suggest that targeting the downstream pathways of glutamine metabolism may be a more effective treatment strategy.

In summary, this paper aims to reveal the adaptation mechanisms of TNBC cells after the loss of the main glutamine transporter and provide a scientific basis for the development of new treatment strategies.